ESWT Treatment For Erectile Dysfunction
ESWT treatment for Erectile Dysfunction
Erectile Dysfunction, also called impotence, is a condition where a man is unable to get or maintain an erection to such an extent that penetration during sexual activity cannot be achieved. The condition can happen at any age but it is far more common in older men.
As men get older, particularly once they have passed the age of 40, it is not unusual to experience changes in their erectile function. This can take the form of the need for more direct stimulation to gain or maintain an erection and a marked decrease in the rigidity of the penis prior to and during sexual intercourse. Other Erectile dysfunction issues may also include the occasional incident of an inability to obtain a full erection, an inability to maintain an erection for the duration of the sexual activity or the inability to achieve an erection at all.
A recent study suggests that over 50% of men aged between 40-70 years have, at some stage, suffered from Erectile Dysfunction of some description and this figure rises to almost 60% for males over the age of 60 and up to 30% those affected are unable to engage in sexual intercourse.
ESWT for erectile Dysfunction has been used overseas for quite a while now and research undertaken recently in Australia has shown that Erectile Dysfunction may be controlled with focused low-medium energy shockwaves. This research has shown very positive results in reducing the need for the reliance on medications or artificial stimulation. The results found that 60% of patients reported an improvement in their erectile function and a total of 50% of all patients involved in the study were able to achieve spontaneous erections which enabled them to engage in penetrative sex following the treatments. Furthermore almost 70% of patients who undertook ESWT for Erectile Dysfunction would recommend the therapy to other patients suffering from this condition.
The process consists of around 5 weekly treatments using low to mid-level energy shockwaves to stimulate a response in the tissue. A total of 3000 shockwaves are administered per session, which usually take between 15-20 minutes. Each treatment begins at a low level of energy and the power level is gradually increased, according to the individual’s tolerance level, to a maximum of 0.25 mJ/mm.
Some discomfort may be felt during the treatment but it should not be painful, this is assessed continually throughout the treatment and the power level can be immediately reduced or stopped at any time in the unlikely event that the treatment becomes too painful.
Research has shown that ESWT for Erectile Dysfunction has no major and very few minor associated risks, there is no anaesthetic requirement and no time off work is needed. It is booked as an outpatient appointment through our clinic for minimal inconvenience or downtime to the patient.
In conclusion, complementing the Dornier EPOS which we use for orthopaedics, with the new Storz Duolith SD1 Ultra will allow us to increase the treatment options at our clinic and as a consequence we are able to offer ESWT treatments for Erectile dysfunction as a very viable, non-invasive and cost effective alternative treatment option when compared to undergoing injections and/or surgery
American Urology Association Foundation (2011). Non-Surgical Management of Erectile Dysfunction (ED). [Online] Available at: http://www.urologyhealth.org/urology/index.cfm?article=60
Chung, E (2015). ‘Peyronie’s disease and low intensity shock wave therapy: Clinical outcomes and patient satisfaction rate in an open-label single arm prospective study in Australian men.’ Korean Journal of Urology, 56, pp 775-780.
Chung, E and Cartmill, R (2015). Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial [Online]. Available at:
Fojecki, Tiessen and Osther (2016). Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain [Online]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27108421
Hatzimouratidis et al (2015). Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation [Online]. Available at: https://uroweb.org/guideline/male-sexual-dysfunction/
Larsen, s. and Levine, L (2011). Peyronie’s Disease: Review of Nonsurgical Treatment Options [Online]. Available at: http://www.sciencedirect.com/science/article/pii/S0094014311000206 (Accessed August 2016).
Olsen et al (2015). Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study [Online]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25470423
Palmieri et al (2011). Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial [Online]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22085227
Sexual Health Australia (2015). Erectile Dysfunction/Impotence [Online]. Available at: http://www.sexualhealthaustralia.com.au/erectile_dysfunction.html
Storz Medical AG (2014). The Boston Medical Group is successful with the DUOLITH® SD1 in the treatment of ED [Online]. Available at: https://www.storzmedical.com/en/easyblog/entry/the-boston-medical-group-is-successful-with-the-duolith-sd1-in-the-treatment-of-ed.html